ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Funding Opportunity: DOD Offering 10.5 Million For Lung Cancer Research

May 30, 2014

Hammer Says President’s Science Advisory to Ask For FY 1985 Supplemental Appropriations for NCI

March 1, 1985

NCAB, DRCCA Board Asked To Consider Dripping All Staff Investigator Salary Support From Core

October 17, 1980

John Montgomery Named to Replace Harold Amos On Cancer Panel

April 8, 1983

Grand Jury Clears Eppley, Shubik

October 24, 1980

In Brief: CTRC Opens New Building With Ceremony For Survivors; WistarWins NASA Grant

June 9, 1995